A novel targeted anti-cancer therapy
Harnessing the power of the immune system to fight cancer is an attractive therapeutic approach. More specifically, conjugating chemotherapeutic drugs to tumour-specific antibodies improves drug delivery and efficiency while minimising side effects. The EU-funded PAC Synthesis project proposes to combine the advantages of protein degradation and antibody targeting into a new therapeutic platform. Scientists will generate conjugates between proteolysis targeting chimeras (PROTAC) and antibodies targeting the myeloid CD33 protein present in acute myeloid leukaemia cells. The employed chemistry ensures conjugate stability in the blood and efficient release of the PROTAC once internalised by cancer cells.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeMSCA-IF-EF-ST - Standard EF
CB2 1TN Cambridge
See on map